体外研究 (In Vitro) |
Telocinobufagin (0.01-100 μM, 0-96 小时) 可抑制人类非小细胞肺癌细胞、骨肉瘤细胞、间变性甲状腺癌 (ATC) 细胞、4T1 乳腺癌细胞和颈部鳞状细胞癌 (HNSCC) 的增殖和转移。
Telocinobufagin (0.125-5 μM, 24-48 小时) 可诱导人类非小细胞肺癌细胞、骨肉瘤细胞和 HNSCC 细胞凋亡。
Telocinobufagin (1-5 μM) 诱导 Cal-27 细胞和 SCC-25 细胞的 G2/M 期阻滞。
Telocinobufagin (0.5 μg/mL) 通过调节 CAL-62 细胞中的 LARP1-mTOR 通路抑制未分化甲状腺癌的恶性转移。
Telocinobufagin (0.1-1 μM,2-48 小时) 阻断 STAT3 和 JAK2/STAT3 信号传导,并抑制 PLK1。
Telocinobufagin (0.05-0.5 μg/mL,24 小时) 可逆转乳腺癌细胞的上皮-间质转化 (EMT) 过程,下调 Snail 转录因子,并抑制 PI3K/Akt/ERK 信号通路。
Telocinobufagin (10-100 nM,24 小时) 可激活肾小管上皮细胞 (HK2 细胞) 和原代正常人肾系膜细胞 (NHMC) 的促纤维化表型,但对 SYF 成纤维细胞无效。
Cell Viability Assay
| Cell Line: |
A549, PC9, and H1299 cells |
| Concentration: |
0.01, 0.1, 1, 10, 100 μM |
| Incubation Time: |
48 h |
| Result: |
Inhibited cell viability in a concentration-dependent manner, and the corresponding half-maximal inhibitory concentrations (IC50) were 124.4, 618.5, and 106.6 nM, respectively. |
Cell Migration Assay
| Cell Line: |
A549, PC9, and H1299 cells |
| Concentration: |
0.125, 0.25 and 0.5 μM |
| Incubation Time: |
PC9 and H1299 cells for 8 h, and A549 cells for 24 h |
| Result: |
Remarkably suppressed cell migration in the Transwell migration assay. |
Apoptosis Analysis
| Cell Line: |
PC9, and H1299 cells |
| Concentration: |
0.125, 0.25 and 0.5 μM |
| Incubation Time: |
24 h (H1299) or 48 h (PC9) |
| Result: |
Increased the apoptotic rates in both cell lines in a concentration-dependent manner. |
Western Blot Analysis
| Cell Line: |
A549, PC9, and H1299 cells |
| Concentration: |
0.25, 0.5 and 1 μM |
| Incubation Time: |
4, 6, 8, 12 h |
| Result: |
Strongly upregulated cleaved PARP1 protein, but down-regulated anti-apoptotic BCL2 protein.
Inhibited STAT3 phosphorylation at tyrosine 705 (Y705) and its downstream targets.
Inhibited STAT3 nuclear translocation in a concentration-dependent manner.
|
Cell Proliferation Assay
| Cell Line: |
143B, HOS, MG63, U2OS, SJSA and Saos-2 cells |
| Concentration: |
0, 0.05, 0.1, 0.2, 0.5 and 1 μM |
| Incubation Time: |
48 h |
| Result: |
Inhibited cell proliferation in six osteosarcoma cell lines in a concentration-dependent manner. |
Cell Migration Assay
| Cell Line: |
143B and HOS cells |
| Concentration: |
0.1, 0.2 and 0.5 μM |
| Incubation Time: |
12 h |
| Result: |
Displayed strong inhibitory activity against tumor cell migration. |
Cell Migration Assay
| Cell Line: |
143B and HOS cells |
| Concentration: |
0.1, 0.2 and 0.5 μM |
| Incubation Time: |
12 h |
| Result: |
Displayed strong inhibitory activity against tumor cell invasion. |
Apoptosis Analysis
| Cell Line: |
143B and HOS cells |
| Concentration: |
0.2 and 0.5 μM |
| Incubation Time: |
48 h |
| Result: |
Significantly induced tumor cell apoptosis. |
Western Blot Analysis
| Cell Line: |
143B, HOS and MG63 cells |
| Concentration: |
0.1, 0.2 and 0.5 μM |
| Incubation Time: |
2, 4, 8, 12, 24, 48 h |
| Result: |
Exhibited a dose-dependent significant inhibition of STAT3 phosphorylation and STAT3 phosphorylation induced by IL-6.
Down-regulated Cyclin D1, Bcl-2, Mcl-1 and Survivin.
Selectively inhibited the phosphorylation of JAK2, and had no significant effect on JAK1 and JAK3.
Down-regulated Snail and vimentin, and up-regulated E-cadherin.
|
RT-PCR
| Cell Line: |
HK2 cells, NHMCs, SYF, SYF + cSrc cells |
| Concentration: |
10 and 100 nM |
| Incubation Time: |
24 h |
| Result: |
Caused a dose-dependent increase in the expression of collagen 1 and collagen 3 mRNA in HK2 cells.
Significantly increased the expression of collagen 1 in NHMCs.
Increased collagen 1, collagen 3, TGFβ, CTGF mRNA.
Did not cause significant changes in the above indicators in the SYF cells.
|
Cell Migration Assay
| Cell Line: |
4T1 cells |
| Concentration: |
0.05 and 0.5 μg/mL |
| Incubation Time: |
24 h |
| Result: |
Concentration-dependently inhibited 4T1 cell migration and significantly reduced the number of cells passed through. |
Cell Invasion Assay
| Cell Line: |
4T1 cells |
| Concentration: |
0.05 and 0.5 μg/mL |
| Incubation Time: |
24 h |
| Result: |
Effectively inhibited the movement of cells through the matrix gel. |
Western Blot Analysis
| Cell Line: |
4T1 cells |
...(内容过长已截断)
体内研究 (In Vivo) |
Telocinobufagin (1-2 mg/kg,腹腔注射,每 2 天一次,共 18 天) 可抑制小鼠人类 NSCLC 异种移植模型中的肿瘤生长。
Telocinobufagin (5-10 mg/kg,腹腔注射,每 2 天一次,共 20 天) 通过抑制小鼠骨肉瘤异种移植模型中的 JAK2/STAT3 信号通路显著抑制肿瘤生长和转移。
Telocinobufagin (10-40 μg,皮下注射,两次剂量,每次间隔 14 天) 可增强 Th1 免疫应答以控制细胞内小鼠中鼠伤寒沙门氏菌感染。
Telocinobufagin (0.062-10 mg/kg,腹腔注射和口服,单剂量) 在小鼠各种急性疼痛模型中表现出强效镇痛作用,并且不依赖于阿片类药物系统或影响运动功能,其镇痛效力是吗啡的四倍。
Telocinobufagin (0.1 mg/kg,腹腔注射,每日一次,共 4 周) 通过 Na+/K+-ATPase 促纤维化信号通路促进肾脏纤维化。
Telocinobufagin (10-20 µg/mouse,腹腔注射,每日三次,共 2 周) 可抑制小鼠 4T1 细胞异种移植模型中的乳腺癌肿瘤生长和上皮间质转化。
Telocinobufagin (4-16 mg/kg,腹腔注射,每日一次,共 30 天) 可抑制小鼠携带 HNSCC 细胞的肿瘤生长,并抑制肺转移.
| Animal Model: |
A549 xenograft tumor model established in female nude mice (BALB/c nude, 4-5-week-old) |
| Dosage: |
1 and 2 mg/kg |
| Administration: |
Intraperitoneal injection (i.p.), every 2 days for a total of 18 days |
| Result: |
Significantly reduced tumor size.
Showed no weight loss and had no noticeable toxicity on the heart, liver, lungs, or kidneys at this concentration.
Reduced the expression of PSTAT3Y705, MCL1, and BCL2 and increased the levels of cleaved PARP1.
|
| Animal Model: |
143B cells xenograft tumor model established in male nude mice (BALB/c nude, 6-8-week-old) |
| Dosage: |
5 mg/kg and 10 mg/kg |
| Administration: |
Intraperitoneal injection (i.p.), every 2 days for a total of 20 days |
| Result: |
Significantly reduced tumor weights.
Reduced the numbers of metastatic nodules.
Reduced the levels of phospho-STAT3 and phospho-JAK2.
Increased the proportion of cleaved caspase-3-positive tumor cells.
|
| Animal Model: |
S. typhimurium infection model established in female ICR mice (five weeks old, Grade II) |
| Dosage: |
10, 20, and 40 μg dissolved in saline |
| Administration: |
Subcutaneous injection (s.c.), two doses on day 1 and day 15 |
| Result: |
Increased the survival rate of mice and reduced bacterial load.
Increased the levels of specific IgG2a (Th1-related antibodies) in OVA and FIST, while the level of IgG1 (Th2-related antibody) did not change significantly.
Promoted the secretion of IFN-γ (a key cytokine for Th1 cells) by spleen cells, but inhibited IL-4 (a marker for Th2 cells) and IL-17A (a marker for Th17 cells).
Upregulated the mRNA expression of the transcription factor T-bet (a key regulatory factor for Th1 cells), while having no significant effect on GATA-3 (Th2) and RORγt (Th17).
|
| Animal Model: |
Acetic acid-induced writhing test, formalin test, tail-flick test, hot-plate test, open-field test, rotarod test established in male Swiss Webster mice (25-30 g) |
| Dosage: |
0.062, 0.125, 0.25, 0.5, and 1 mg/kg (i.p.) and 0.625, 1.125, 2.5, 5, and 10mg/kg (p.o.) |
| Administration: |
Intraperitoneal injection (i.p.) and oral administration (p.o.), single dose |
| Result: |
Significantly inhibited the number of contortions in mice in a dose-dependent manner.
Significantly inhibited the licking time during the first 5 minutes after intraplantar injection of formalin.
Significantly increased the reaction time (the withdrawal by a brief vigorous movement) in a dose-dependent manner.
Significantly increased the reaction time (the withdrawal by a brief vigorous movement) in a dose-dependent manner.
Presented significant reaction latencies for 3 hours after administration (1 mg/kg, i.p; 10 mg/kg, p.o).
Did not affect locomotion in mice in open-field test and rotarod test.
Exhibited the potency about 4 times higher than that of morphine.
|
| Animal Model: |
Measurement of renal fibrosis model established in wild-type male SvJ/Black Swiss mice (25-30 g) (WT), as well as SvJ/Black Swiss mice heterozygous for the Na+/K+-ATPase-α-1 (referred to as NKA α-1+/−) |
| Dosage: |
0.1 mg/kg |
| Administration: |
Intraperitoneal injection (i.p.), once daily for 4 weeks |
| Result: |
Caused a significant increase in systolic blood pressure in both wild-type mice and NKAα-1+/− mice, but at 4 weeks, the amount of urinary protein excreted by NKAα-1+/− mice was significantly less than that of the wild-type control group.
Resulted in mild to moderate periglomerular and peritubular fibrosis of the renal cortex and the degree of renal fibrosis in NKAα-1+/− mice was lower than that in the wild-type control group at 4 weeks.
|
| Animal Model: |
4T1 cells xenograft tumor model established in six week old female BALB/c nude mice (18 22 g) |
| Dosage: |
10 or 20 µg/mouse |
| Administration: |
Intraperitoneal injection (i.p.), three times a week for two consecutive weeks. |
| Result: |
Significantly reduced the tumor volume and weight.
Reduced the number of lung metastatic lesions
Observed EMT markers and signaling pathway proteins in tumor tissues consistent with those in the in vitro experiments.
|
| Animal Model: |
Cal-27 cells xenograft tumor model and normal or PLK1 over-expressed HNSCC cells induced lung metastasis model established in BALB/c nude mice |
| Dosage: |
4, 8, and 16 mg/kg (xenograft tumor model) and 8 mg/kg (lung metastasis model) |
| Administration: |
Intraperitoneal injection (i.p.), once daily for 30 days |
| Result: |
Significantly inhibited the growth of transplanted tumors and lung metastasis.
Downregulated the expressions of PLK1, CDC25c and Ki67 in tumor tissues and overexpression of PLK1 can completely reverse the anti-tumor effect of TBG.
|
|
| 性状 |
固体 |
| 颜色 |
White to off-white |
| 分子量 |
402.52 |
| 分子式 |
C24H34O5 |
| CAS No. |
472-26-4 |
| 别名 |
远华蟾蜍精; Telobufotoxin; Telocinobufogenin |
| 体内实验配方 |
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.97 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 |
| 储存方式 |
| Powder |
-20°C |
3 years |
|
4°C |
2 years |
| In solvent |
-80°C |
2 years |
|
-20°C |
1 year |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
溶液配制表
|
DMSO 中的溶解度 : 50 mg/mL (124.22 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO) | 可选溶剂 | 浓度 | 1 mg | 5 mg | 10 mg | 25 mg |
|---|
| DMSO | 1 mM | 2.4843 mL | 12.4217 mL | 24.8435 mL | 62.1087 mL | | 5 mM | 0.4969 mL | 2.4843 mL | 4.9687 mL | 12.4217 mL | | 10 mM | 0.2484 mL | 1.2422 mL | 2.4843 mL | 6.2109 mL | | 15 mM | 0.1656 mL | 0.8281 mL | 1.6562 mL | 4.1406 mL | | 20 mM | 0.1242 mL | 0.6211 mL | 1.2422 mL | 3.1054 mL | | 25 mM | 0.0994 mL | 0.4969 mL | 0.9937 mL | 2.4843 mL | | 30 mM | 0.0828 mL | 0.4141 mL | 0.8281 mL | 2.0703 mL | | 40 mM | 0.0621 mL | 0.3105 mL | 0.6211 mL | 1.5527 mL | | 50 mM | 0.0497 mL | 0.2484 mL | 0.4969 mL | 1.2422 mL | | 60 mM | 0.0414 mL | 0.2070 mL | 0.4141 mL | 1.0351 mL | | 80 mM | 0.0311 mL | 0.1553 mL | 0.3105 mL | 0.7764 mL | | 100 mM | 0.0248 mL | 0.1242 mL | 0.2484 mL | 0.6211 mL |
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|